Combination of DNA repair inhibition with bendamustine or gemcitabine in the treatment of cancer
AssigneeInstitute For Cancer Research
InventorsAlfonso Bellacosa, Timothy Yen, Neil Beeharry, Mitchell Smith, Rossella Tricarico, Vikram Bhattacharjee, Pietro Mancuso
Life of this patent
Estimating the term…
Abstract
The invention provides methods for enhancing the cytotoxicity of DNA damage in cancer cells that express thymine DNA glycosylase, and treating tumors accordingly. The methods comprise inhibiting the expression or biologic activity of thymine DNA glycosylase, and inducing DNA damage in the cancer cells. DNA damage may be induced by administration of bendamustine or gemcitabine to the cancer cells.
Claims12
A method for treating a pancreatic tumor or lung tumor that expresses thymine DNA glycosylase (TDG), comprising administering to a human patient having a pancreatic tumor or lung tumor that expresses TDG an effective amount of bendamustine or gemcitabine and an effective amount of juglone, cefixime, or closantel, thereby treating the tumor in the patient, wherein the combination produces synergistic killing of tumor cells.
A method for treating a pancreatic tumor that expresses thymine DNA glycosylase (TDG), comprising administering to a human pancreatic cancer patient in need thereof an effective amount of bendamustine or gemcitabine in combination with an effective amount of a TDG inhibitor selected from the group consisting of juglone, closantel, and cefixime, thereby treating the pancreatic tumor in the patient, wherein the combination produces synergistic killing of pancreatic tumor cells.
A method for treating a breast tumor that expresses thymine DNA glycosylase (TDG), comprising administering to a human breast cancer patient in need thereof an effective amount of bendamustine or gemcitabine in combination with an effective amount of a TDG inhibitor selected from the group consisting of juglone, closantel, and cefixime, thereby treating the breast tumor in the patient, wherein the combination produces synergistic killing of breast tumor cells.
A method for treating melanoma expressing thymine DNA glycosylase (TDG), comprising administering to a human melanoma patient in need thereof an effective amount of bendamustine or gemcitabine in combination with an effective amount of a TDG inhibitor selected from the group consisting of juglone, closantel, and cefixime, thereby treating melanoma in the patient, wherein the combination produces synergistic killing of melanoma cells.
Dependencies are inferred from the claim text.